Pharmaceutical - AstraZeneca, Rare diseases

Filter

Current filters:

AstraZenecaRare diseases

Popular Filters

Mixed FDA advisory panel votes on Bristol-Myers and AstraZeneca's metreleptin

Mixed FDA advisory panel votes on Bristol-Myers and AstraZeneca's metreleptin

12-12-2013

In an 11 to one vote yesterday, the US Food and Drug Administration’s Endocrinologic and Metabolic…

AstraZenecaBristol-Myers SquibbMetabolicsmetreleptinNorth AmericaPharmaceuticalRare diseasesRegulation

EU approval for AstraZeneca thyroid cancer drug Caprelsa

21-02-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this morning that the European Commission has…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalRare diseasesRegulation

Back to top